[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360513-105":59,"doc-detail-360513-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-genomic-profiles-of-patients-with-biliary-tract-cancer-research-article","Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer - Research Article","","Biliary tract cancer (BTC) is an aggressive, heterogeneous malignancy with high lethality and poor clinical outcomes. This study evaluates genomic profiles in 134 BTC patients using targeted panel sequencing, integrating clinicopathologic data, treatment details, and clinical outcomes. Frequent alterations include TP53 and KRAS, with subtype- and disease-site–specific patterns compared with Western cohorts. Selected variants also show significant associations with progression-free and overall survival, with ICGC validation supporting TP53 as linked to worse outcomes across subtypes and therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-genomic-profiles-of-patients-with-biliary-tract-cancer-research-article/360513/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-genomic-profiles-of-patients-with-biliary-tract-cancer-research-article/360513.png","ImageObject",300,407,{"name":92,"@type":93},"Grenda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the genomic study on biliary tract cancer (BTC)?","Question",{"text":112,"@type":113},"To evaluate genomic profiles in BTC and support development of precision medicine approaches. The work aims to better understand genomic alterations and their clinical implications.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were genomic profiles generated and analyzed in the study?",{"text":117,"@type":113},"Targeted panel sequencing was performed on 134 BTC patients, and genomic testing results were analyzed alongside clinicopathologic data including treatment information and clinical outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which genomic alterations were most frequent, and what did survival analysis show?",{"text":121,"@type":113},"The most frequent alterations included TP53 (55.5%), KRAS (38.1%), ARID1A (17.2%), and CDKN2A (15.7%). Several alterations were significantly associated with progression-free survival (PFS) and overall survival (OS), and ICGC validation supported TP53’s link to inferior outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360513,1790259711,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nComprehensive Genomic Profiles of Patients With Biliary Tract Cancer  \nXia Yang1,2  | Tao Zhu1 | Xiaotong Hu1 | Zhinong Jiang1 | Hongchuan Jin2  \n1Department of Pathology, Sir Run Run Shaw Hospital of Zhejiang University, Zhejiang, Hangzhou, China | 2Department of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China  \nCorrespondence: Hongchuan Jin ([jinhc@zju.edu.cn](jinhc@zju.edu.cn))  \nReceived: 10 October 2025 | Revised: 18 March 2026 | Accepted: 19 May 2026  \nKeywords: biliary tract cancer | prognosis | targeted next-generation sequencing  \nABSTRACT  \nPurpose: Biliary tract cancer (BTC) represents a heterogeneous disease with highly lethal malignancy and poor clinical outcomes. Here, we aimed to evaluate its genomic profiles to promote the development of precision medicine for BTC.  \nMaterials and Methods: Genomic analysis of 134 BTC patients was performed by using targeted panel sequencing in this study. The results of genomic testing were analyzed by integrating patients' clinicopathologic data, including treatment information and clinical outcomes. The significance of genetic alterations in our cohort was compared with western BTCs by using public repositories NGS data from ICGC cohort.  \nResults: The most frequent genomic alterations were TP53 (55.5%), KRAS (38.1%), ARID1A (17.2%), and CDKN2A (15.7%) in our cohort. Notably, Chinese BTC patients had a higher prevalence of TP53, KRAS, and LRP1B alterations compared with Western BTCs. Moreover, a higher frequency of IDHand FGFR2 alterations was found in intrahepatic cholangiocarcinoma (ICA), whereas BRIP1, KRAS, and POLE alterations were more likely to accumulate in extrahepatic cholangiocarcinoma (ECA), and those with gallbladder carcinoma (GBC) had a higher prevalence of NF1, MSH3, and PIK3R1 alterations. Furthermore, several genomic alterations were observed to have a significant impact on progression-free survival (PFS) and overall survival (OS) in our cohort. NGS data from the ICGC cohort further validated that TP53 was associated with inferior clinical outcomes both in Chinese and Western BTC patients, regardless of histopathologic subtypes or therapeutic approaches.  \nConclusion: We demonstrated the real-world genomic characteristics of BTC patients, which may have promising implications for the development and application of precision medicine in the future. Well-designed prospective studies are mandatory to validate the predictive role of significant genomic alterations observed in our study.  \n1 | Introduction  \nBiliary tract cancer (BTC) represents an aggressive, heterogeneous biliary epithelial neoplasm with highly lethal malignancy and poor clinical outcomes [1] . It is mainly composed of three subtypes in terms of anatomic regions, including intrahepatic cholangiocarcinoma (ICA), extrahepatic cholangiocarcinoma (ECA), and gallbladder carcinoma (GBC) [2] . Surgical resection remains the primary curative treatment for BTC, but most patients are diagnosed with unresectable disease due to inadequate  \nearly detection tools, difficult anatomical access, and aggressive tumor biology [3] . Hence, there is an urgent need to comprehensively understand the genomic profile and thus explore novel agent development for accurately predicting clinical outcomesand providing therapeutic approaches for BTC.  \nCurrently, several treatment options including chemotherapy, targeted therapy, and immunotherapy were introduced for advanced BTC patients [4, 5], of which gemcitabine-based chemotherapy has become the standard first-line treatment  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s). Cancer Medicine p","cbCaiaWCvYl9PNtt","https://ap.wps.com/l/cbCaiaWCvYl9PNtt","pdf",2957706,11,"English","# Introduction\n## Disease background and unmet needs\n## Precision medicine and molecular testing\n# Materials and Methods\n## Patient cohort and targeted panel sequencing\n## Integration of clinical and genomic data\n# Results\n## Most frequent genomic alterations\n## Differences across BTC subtypes and sites\n## Associations with PFS and OS\n# Discussion/Conclusion\n## Real-world genomic characteristics and validation\n## Need for prospective studies","[{\"question\":\"What was the purpose of the genomic study on biliary tract cancer (BTC)?\",\"answer\":\"To evaluate genomic profiles in BTC and support development of precision medicine approaches. The work aims to better understand genomic alterations and their clinical implications.\"},{\"question\":\"How were genomic profiles generated and analyzed in the study?\",\"answer\":\"Targeted panel sequencing was performed on 134 BTC patients, and genomic testing results were analyzed alongside clinicopathologic data including treatment information and clinical outcomes.\"},{\"question\":\"Which genomic alterations were most frequent, and what did survival analysis show?\",\"answer\":\"The most frequent alterations included TP53 (55.5%), KRAS (38.1%), ARID1A (17.2%), and CDKN2A (15.7%). Several alterations were significantly associated with progression-free survival (PFS) and overall survival (OS), and ICGC validation supported TP53’s link to inferior outcomes.\"}]","Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer - Research Article | PDF",1790140339,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7232c6173379f1136efe6fc335cc4a65.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45b853acf988b36a7a2ff318de29982e.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da81678262f6da49f1ac1a0ccaf87c2e.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9cf67b8ae0516ce56690a169a32086f.webp",980,1287]